Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research (Q30419845)

16 August 2017

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research (English)

1 reference

16 August 2017

1 reference

10

Muin J Khoury

1 reference

16 August 2017

6

Sheri D Schully

1 reference

Heather Spencer Feigelson

16 August 2017

5

object named as

Heather Spencer Feigelson

1 reference

16 August 2017

11

David L Veenstra

1 reference

16 August 2017

7

Scott Ramsey

1 reference

16 August 2017

3

Evelyn Whitlock

1 reference

16 August 2017

8

Sean Tunis

1 reference

16 August 2017

Katrina A B Goddard

1

1 reference

16 August 2017

William A Knaus

2

1 reference

16 August 2017

Gary H Lyman

4

1 reference

16 August 2017

Andrew N Freedman

9

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

7

1 reference

16 August 2017

633-642

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

16 August 2017

1 reference

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A CTSA agenda to advance methods for comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Horizon scanning for new genomic tests

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The promise and realities of comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Comparative effectiveness research: Policy context, methods development and research infrastructure

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Cost-effectiveness analysis in pharmacogenomics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Stakeholder perspectives on a risk-benefit framework for genetic testing

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Performance of common genetic variants in breast-cancer risk models

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Health spending projections through 2019: the recession's impact continues

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Access with evidence development: the US experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Coverage with Evidence Development: applications and issues

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Translational research in cancer genetics: the road less traveled

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Expectations, validity, and reality in pharmacogenetics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Realising the potential of the family history in risk assessment and primary prevention of coronary heart disease in primary care: ADDFAM study protocol

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Curses--winner's and otherwise--in genetic epidemiology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Why Most Discovered True Associations Are Inflated

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Internal and external validity of cluster randomised trials: systematic review of recent trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Replicating genotype-phenotype associations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Developments in post-marketing comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Using value of information analysis to prioritise health research: some lessons from recent UK experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A review of uses of health care utilization databases for epidemiologic research on therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Design and analysis of group-randomized trials: a review of recent practices

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Using routine comparative data to assess the quality of health care: understanding and avoiding common pitfalls

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The historical and moral imperatives of comparative effectiveness research.

20 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Familial risk for common diseases in primary care: the Family Healthware Impact Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

What is the clinical utility of genetic testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Bayesian and classical estimation of mixed logit: An application to genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

How best to engage patients, doctors, and other stakeholders in designing comparative effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Evaluating the utility of personal genomic information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

On the limitations of comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Principles and indicators of successful consumer involvement in NHS research: results of a Delphi study and subgroup analysis

21 January 2018

1 reference

12 December 2020

Modeling comparative effectiveness and the value of research

1 reference

12 December 2020

The cross-validated adaptive signature design

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?

1 reference

12 December 2020

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

12 December 2020

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/GIM.2012.16

1 reference

16 August 2017

1 reference

16 August 2017

1 reference